JP5199878B2 - Ｔｏｌｌ様受容体３モジュレーター、方法および用途 - Google Patents

Ｔｏｌｌ様受容体３モジュレーター、方法および用途 Download PDF

Info

Publication number
JP5199878B2
JP5199878B2 JP2008538188A JP2008538188A JP5199878B2 JP 5199878 B2 JP5199878 B2 JP 5199878B2 JP 2008538188 A JP2008538188 A JP 2008538188A JP 2008538188 A JP2008538188 A JP 2008538188A JP 5199878 B2 JP5199878 B2 JP 5199878B2
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
amino acid
tlr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008538188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523010A5 (https=
JP2009523010A (ja
Inventor
デユフイ，カレン・イー
フアング，チヨング・シー
ラム，ロバータ
ボウ，ムーハマドウ・エル
サリスキ，ロバート・テイ
サン，マテオ・ラニ
Original Assignee
セントカー・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントカー・インコーポレーテツド filed Critical セントカー・インコーポレーテツド
Publication of JP2009523010A publication Critical patent/JP2009523010A/ja
Publication of JP2009523010A5 publication Critical patent/JP2009523010A5/ja
Application granted granted Critical
Publication of JP5199878B2 publication Critical patent/JP5199878B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008538188A 2005-10-27 2006-10-26 Ｔｏｌｌ様受容体３モジュレーター、方法および用途 Expired - Fee Related JP5199878B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73079305P 2005-10-27 2005-10-27
US60/730,793 2005-10-27
PCT/US2006/060305 WO2007051164A2 (en) 2005-10-27 2006-10-26 Toll like receptor 3 modulators, methods and uses

Publications (3)

Publication Number Publication Date
JP2009523010A JP2009523010A (ja) 2009-06-18
JP2009523010A5 JP2009523010A5 (https=) 2009-09-17
JP5199878B2 true JP5199878B2 (ja) 2013-05-15

Family

ID=37968676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008538188A Expired - Fee Related JP5199878B2 (ja) 2005-10-27 2006-10-26 Ｔｏｌｌ様受容体３モジュレーター、方法および用途

Country Status (6)

Country Link
US (1) US7718778B2 (https=)
EP (1) EP1945820B1 (https=)
JP (1) JP5199878B2 (https=)
DK (1) DK1945820T3 (https=)
ES (1) ES2435775T3 (https=)
WO (1) WO2007051164A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147956A2 (en) * 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
WO2009086352A2 (en) * 2007-12-26 2009-07-09 Centocor, Inc. Cynomolgus toll-like receptor 3
ES2360334T3 (es) * 2008-06-27 2011-06-03 Theranor Sprl Composiciones farmacéuticas de anticuerpos para enfermedades causadas por virus.
EP2356216B1 (en) * 2008-10-03 2016-06-01 Janssen Biotech, Inc. Papio cynocephalus toll-like receptor 3
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
RS55861B1 (sr) 2008-10-31 2017-08-31 Janssen Biotech Inc Antagonisti toll-like receptora 3
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137787A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
SI2425008T1 (sl) * 2009-04-29 2015-12-31 Janssen Biotech, Inc. Antagonisti tollu podobnega receptorja 3
EP2451844B1 (en) 2009-07-10 2015-04-22 Innate Pharma Tlr3 binding agents
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
US20140065154A1 (en) 2011-01-12 2014-03-06 Innate Pharma Tlr3 binding agents
WO2013178736A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
US10370451B2 (en) * 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
JP2021506827A (ja) * 2017-12-15 2021-02-22 シルバーバック セラピューティックス インコーポレイテッド 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2331622T3 (es) 1997-05-07 2010-01-11 Schering Corporation Proteinas receptoras humanas similares a toll, reactivos y metodos relacionados.
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
PT1887014E (pt) * 1997-10-17 2010-07-05 Genentech Inc Homëlogos de toll humana
EP1158989B1 (en) 1999-03-09 2007-06-20 Anker, Stefan Use of inhibitors of endotoxin for the treatment of cachexia
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP2005501917A (ja) 2001-09-07 2005-01-20 ザ トラスティーズ オブ ボストン ユニバーシティ 免疫複合体関連疾患を処置するための方法および組成物
CN1633598A (zh) 2001-10-05 2005-06-29 科勒制药股份公司 Toll样受体3信号传导的激动剂和拮抗剂
US20060058288A1 (en) 2002-04-08 2006-03-16 Masayuki Ii Severe sepsis preventive therapeutic agent
DK1545597T3 (da) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
US20050158799A1 (en) * 2003-10-17 2005-07-21 Fitzgerald Katherine A. TRIF-related adaptor molecule (TRAM) and uses thereof
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos

Also Published As

Publication number Publication date
EP1945820A2 (en) 2008-07-23
WO2007051164A8 (en) 2008-06-12
US20070098716A1 (en) 2007-05-03
EP1945820A4 (en) 2009-02-18
DK1945820T3 (da) 2013-11-11
WO2007051164A2 (en) 2007-05-03
WO2007051164A3 (en) 2007-11-29
JP2009523010A (ja) 2009-06-18
ES2435775T3 (es) 2013-12-23
EP1945820B1 (en) 2013-08-28
US7718778B2 (en) 2010-05-18

Similar Documents

Publication Publication Date Title
JP5199878B2 (ja) Ｔｏｌｌ様受容体３モジュレーター、方法および用途
ES2963598T3 (es) Dominios de unión al antígeno humanizado contra CD19 y métodos de uso
TWI487535B (zh) 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
WO2020063787A1 (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
JP2023106392A (ja) Ｃｄ３抗原結合性断片及びその使用
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
CN106967172A (zh) 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途
JP2006508689A (ja) 選択的ＩＦＮ−γ経路インヒビターとしてのヒト抗ＩＦＮ−γ中和抗体
KR20070026522A (ko) 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법
US20220185882A1 (en) Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
CN113382752B (zh) Cd137激动剂抗体及其用途
US20090136509A1 (en) Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions
US20140255388A1 (en) Toll like receptor 3 antagonists, methods and uses
US20240182594A1 (en) Uses of antagonist, non-depleting ox40 antibodies
JP2025178293A (ja) アゴニスト抗ｃｄ４０抗体
WO2022002065A1 (zh) 抗cd40抗体或抗原结合片段及其应用
CN118562015A (zh) 一种针对cd20/cd3的双异性抗体及其制备方法和应用
JPWO2016143702A1 (ja) 抗ヒト膜型ａｄａｍ２８抗体
CN101415438B (zh) Toll样受体3拮抗剂、方法和用途
CN120098124A (zh) 一种抗bdca-2抗体及其制备方法和应用
CN119285769A (zh) 多特异性抗体及其医药用途
HK40121520A (zh) 抗-tnfr2抗体及其使用方法
HK1131744B (en) Toll like receptor 3 antagonists, methods and uses
AU2012241182A1 (en) Toll like receptor 3 antagonists, methods and uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130208

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160215

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5199878

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees